We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
- Authors
Wu, P‐C; Wu, C‐J; Lin, C‐J; Pan, C‐F; Chen, C‐Y; Huang, T‐M; Wu, C‐H; Lin, S‐L; Chen, Y‐M; Chen, L; Wu, V‐C
- Abstract
Few studies evaluated the effects of pentoxifylline on hard endpoints in patients with predialysis stage 5 chronic kidney disease (CKD). Thus, we tried to explore the effects of pentoxifylline and its interaction with renin-angiotensin-aldosterone system (RAAS) blockade on the development of endstage renal disease (ESRD) and mortality. This nationwide cohort study retrospectively included patients who had a serum creatinine level of >6 mg/dL and received erythropoiesis-stimulating agents (ESAs) between 2000 and 2010. We analyzed 7,366 pentoxifylline users and 7,366 propensity score-matched nonusers. Using Cox proportional hazard models, pentoxifylline reduced the risks of ESRD and the composite renal outcome but not that of mortality. In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy. This study suggests pentoxifylline is efficacious in slowing progression to ESRD in patients with predialysis stage 5 CKD.
- Subjects
PENTOXIFYLLINE; DRUG efficacy; CHRONIC kidney failure complications; RENIN-angiotensin system; HEMODIALYSIS complications; DISEASE progression; THERAPEUTICS
- Publication
Clinical Pharmacology & Therapeutics, 2015, Vol 98, Issue 4, p442
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.173